CH₃CH₃
official

9-ODM (9-O-demethylmitragynine): experiences

by ch3ch3 · 8h ago · 0 comments

This section is for first-hand accounts of 9-ODM: the tablets sold since mid-2026 as 9-ODM, 9ODM, MIT-9, MIT9 or C9. Read the 9-ODM entry's other sections first. No study has ever given 9-ODM to people, so first-hand reports are close to all there is, and that is a reason for more caution, not less.

One community report (UNVERIFIED)

The site has one report so far. It comes from one anonymous adult and reached the site second-hand. Nobody has checked it, it names no product, and there is no way to know what the tablets actually contained. In the words it was relayed in:

short-lived euphoria followed by sedation; needs a much higher amount per mg than 7-OH
for a similar effect; current commercial products taste foul; the user noticed few
negative effects.

What this does not tell you. It is one person, once, and it is not guidance.

  • "A much higher amount per mg than 7-OH." This is not a conversion and not a dose. Products under these names are not reliably what they say: certificates published for one brand's MIT-9 tablets found mitragynine and no 9-ODM at all (the general section and the certificates deep dive cite them). So "more" may mean a different compound, a different strength, or a blend. Amounts do not carry over between products, between people, or from 7-OH to anything else.
  • "Few negative effects." That describes one person's short-term impression. It is not a safety finding. Dependence, tolerance and withdrawal build up with repeated use and do not show in a short report. Nobody has published human safety data on 9-ODM.

The known risks, next to it

9-ODM acts on the mu-opioid receptor in animal tissue, the receptor morphine acts on. So until people are studied, the opioid class risks apply (see the general and interactions sections, with their citations):

  • Dependence, tolerance and withdrawal. For its close relative 7-OH, the American College of Medical Toxicology's August 2026 position statement reports dependence, tolerance and withdrawal typical of other opioids. For 9-ODM there are no human data either way.
  • Slowed breathing with other depressants. Alcohol, benzodiazepines, gabapentin or pregabalin, other opioids, and 7-OH or kratom products all add to the risk. That is a class inference, and it is the combination that puts people in hospital.
  • Unknown contents. The name on the pack does not settle which compound is inside, or how much.
  • Naloxone. It blocked 9-ODM's effect in animal tissue. Keep it nearby, and if breathing slows or stops, call emergency services.

How to write one worth reading

Name the product form and what the label claimed, whether a certificate was published and what it found, how often and for how long you used it, what else was in your system, and above all what happened when you stopped or ran out. Withdrawal accounts are the most useful thing this page could hold. No sourcing talk, no brand recommendations. Describe what happened; don't prescribe.

The chemistry, interactions and legal sections of this area carry what the evidence supports, with citations. This page is for what happened to you.

0

Comments

Sign in to join the conversation.

No comments yet.

Tell us something